Coherus Appoints Juliana M. Reed, Vice President, Government Affairs
September 21 2015 - 8:46PM
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play,
global biosimilars company with late-stage clinical products, today
is pleased to announce the appointment of Juliana M. Reed as Vice
President, Government Affairs. Ms. Reed joins Coherus with over 10
years in government affairs, specializing in global biosimilars
policy.
"We welcome Juliana to the Coherus team," said Denny Lanfear,
President and Chief Executive Officer of Coherus. "Juliana is an
accomplished executive who brings a wealth of experience, insight
and leadership in the development of government policies that
impact this new industry. The Coherus leadership team is composed
of successful veterans who have helped pioneer the biologics
industry. With the addition of Juliana, we now have one of the
recognized leading experts on global biosimilar public policy.
We look forward to working with Juliana in our efforts
towards bringing affordable medications to patients and creating a
vibrant marketplace for biosimilars in the US."
"I am thrilled to join Coherus," said Ms. Reed. "The team
is driven by a common mission and passion to expand patient access
to important medicines by developing biosimilars to biologics that
have been on markets for years. It is an honor and a privilege
to join them on this mission."
Ms. Reed has extensive experience in governmental and public
affairs in the healthcare, pharmaceutical and medical device
industries, including roles with Baxter and Hospira. Juliana led
the development and execution of the Hospira global biosimilars
public policy strategy for the last 10 years, prior to the recent
Pfizer acquisition of Hospira. Juliana is the current
President of the Biosimilars Forum, a not for profit group
representing the US biosimilars industry. The members of the
Biosimilars Forum represent the largest pipeline of biosimilars in
development in the US. Juliana earned her BS from Marquette
University and her MS from DePaul University.
About Coherus BioSciences, Inc.
Coherus is a pure-play biosimilar platform company that develops
and commercializes high-quality therapeutics for major regulated
markets. Biosimilars are intended for use in place of existing,
branded biologics to treat a range of chronic and often
life-threatening diseases, with the potential to reduce costs and
expand patient access. Composed of a team of proven industry
veterans with world-class expertise in process science, analytical
characterization, protein production and clinical-regulatory
development, Coherus is positioned as a leader in the global
biosimilar marketplace. Coherus is advancing three late-stage
clinical products towards commercialization, CHS-1701
(pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and
CHS-1420 (adalimumab biosimilar), as well as developing a robust
pipeline of future products. For additional information, please
visit www.coherus.com.
CONTACT: Keith Vendola, M.D.
Investor Relations
Coherus BioSciences, Inc.
kvendola@coherus.com
+1 (650) 437-6239
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024